Nutrition Therapy in the Hospital
Review: Enteral Nutrition in Hospitalized Adults
21 Apr, 2025 | 13:23h | UTCIntroduction:
This is a summary of a new review published in the New England Journal of Medicine discussing the rationale, evidence, and practical considerations for administering enteral nutrition to hospitalized adults. The main objective is to provide guidance on identifying patients with disease-related malnutrition, initiating enteral feeding, and differentiating strategies for critically ill versus non–critically ill patients who require nutritional support.
Key Recommendations:
-
Identify Malnutrition Early:
-
Screen all hospitalized patients for malnutrition (e.g., using the Malnutrition Screening Tool) on admission.
-
Confirm high-risk cases with a comprehensive nutrition assessment (e.g., GLIM or AAIM criteria).
-
-
Optimize Oral Intake First:
-
Whenever possible, use strategies such as dietary modifications and oral nutritional supplements before initiating enteral nutrition.
-
Implement medical nutrition therapy with the goal of meeting at least 75% of estimated energy and protein requirements orally; consider EN/PN if this goal is not reached within approximately 5 days.
-
-
Initiate Enteral Nutrition if Oral Intake Is Inadequate:
-
Consider enteral feeding for patients who fail to meet energy and protein goals and do not have contraindications (e.g., intestinal obstruction, severe shock, intestinal ischemia, or active gastrointestinal hemorrhage).
-
Dosing considerations differ significantly by patient population and clinical phase:
-
In critical illness (acute phase, first week), evidence suggests potential harm from early full caloric feeding or high protein doses (e.g., ≥2.2 g/kg/day), particularly in patients with shock or organ failure. A more “trophic” or hypocaloric approach (<70% of estimated energy needs) is often appropriate, especially if there is acute kidney injury or multiorgan dysfunction.
-
In contrast, for non–critically ill medical or surgical patients at risk of malnutrition, studies show that underfeeding is associated with worse outcomes, making it important to achieve closer to full nutritional requirements sooner.
-
-
-
Select the Appropriate Route and Timing:
-
For short-term use (up to 6 weeks), place a nasoenteric tube.
-
For anticipated long-term support, consider a gastrostomy or jejunostomy tube.
-
Postpyloric feeding (duodenal or jejunal) may reduce aspiration risk in certain patients.
-
-
Adjust Dose According to Clinical Phase:
-
In the ICU acute phase, avoid early full feeding; consider “trophic” or hypocaloric regimens.
-
As the patient recovers from critical illness, gradually increase caloric and protein delivery to meet estimated needs if tolerated, though exact targets remain under investigation.
-
In non–critically ill patients, aim to meet estimated requirements unless specific clinical issues necessitate lower delivery.
-
-
Mitigate Complications:
-
Use continuous pump-assisted infusion, though volume-based feeding can improve goal attainment.
-
Monitor regularly for refeeding syndrome (e.g., hypophosphatemia, hypokalemia, hypomagnesemia) and correct electrolyte abnormalities.
-
Employ glucose management strategies to avoid hyperglycemia.
-
-
Coordinate Interdisciplinary Care:
-
Engage dietitians, nursing staff, pharmacists, and other professionals to tailor therapy and optimize patient acceptance.
-
Involve patients in shared decision-making, particularly regarding personal values and treatment goals.
-
Conclusion:
These recommendations underscore enteral nutrition’s essential role in preventing and treating disease-related malnutrition. However, the direct impact on major outcomes (e.g., mortality, complications) varies by patient population, feeding strategy, and timing. In critically ill patients, especially during the first week of ICU care, lower-dose or “trophic” enteral feeding may be safer, whereas non–critically ill patients generally benefit from achieving nutritional targets more fully. Our understanding of optimal feeding approaches continues to evolve, particularly with regard to feeding dose during different phases of illness and recovery.
Review: Nutritional Support in Critically Ill Patients
6 Jan, 2025 | 11:00h | UTCIntroduction: This summary is derived from a state-of-the-art review on nutritional support in the intensive care unit (ICU) published in The BMJ. Critically ill patients experience metabolic disturbances, inflammation, and profound muscle wasting. Nutritional therapy aims to mitigate these effects, though recent randomized controlled trials (RCTs) challenge the dogma of early, aggressive provision of high-calorie and high-protein diets for all ICU patients. Instead, emerging evidence indicates that moderate energy and protein restriction, particularly during the first week, may enhance recovery and reduce complications such as hospital-acquired infections, muscle weakness, and ICU-acquired morbidity. Nonetheless, identifying ideal feeding strategies remains complex, given the dynamic nature of critical illness and the interplay with other interventions such as sedation and physical rehabilitation.
Key Recommendations:
- Individualized Timing and Dose: Limit caloric and protein loads during the acute phase (roughly the first seven days), especially in patients with hemodynamic instability or shock. Later, as patients transition to recovery, gradually increase macronutrient delivery to meet evolving metabolic needs.
- Preferred Feeding Route: Enteral nutrition is generally recommended when the gastrointestinal tract is functional, particularly after shock resolution. Parenteral nutrition can be reserved for prolonged gut dysfunction or inability to meet needs enterally. Studies comparing enteral versus parenteral feeding have shown no clear outcome differences, but early enteral feeding is often favored for physiological and cost reasons.
- Avoid Overfeeding and Overzealous Protein Provision: Several large RCTs (including EFFORT-Protein, EDEN, and NUTRIREA-3) observed no mortality benefit—and in some instances, worse outcomes—when patients received full or high doses of energy and protein in the first week. Metabolic “resistance” and inhibition of protective processes such as autophagy might explain why restricted early feeding sometimes confers advantages.
- Monitoring and Assessment: Traditional tools (NUTRIC, NRS-2002) and biomarkers (albumin, prealbumin) do not reliably predict who benefits from higher or lower feeding levels. Ultrasound or computed tomography to assess muscle mass may hold promise, but no validated approach exists to guide individualized macronutrient targets.
- Micronutrients and Specialized Formulations: Broad-spectrum pharmaconutrients (glutamine, antioxidants, etc.) have not improved outcomes in well-powered trials. Instead, standard vitamin and trace element supplementation consistent with recommended daily allowances appears sufficient in most cases.
- Long-term Rehabilitation: Combined nutritional support and physical exercise are critical for mitigating long-term impacts of ICU-acquired weakness and functional decline. Evidence increasingly highlights the need for prolonged, structured rehabilitation to optimize muscle recovery and quality of life.
Conclusion: Although nutritional support remains central to critical care, it is most effective when carefully adapted to disease phase, patient comorbidities, and evolving organ dysfunction. Key evidence suggests a more conservative approach to energy and protein during the acute phase, followed by gradual escalation and integration with rehabilitation. Ongoing research seeks to identify physiological markers that distinguish when to intensify nutritional therapy and how best to align macronutrient delivery with other therapies to promote muscle function and reduce complications.
Reference: Reignier J, Rice TW, Arabi YM, Casaer M. Nutritional Support in the ICU. BMJ. 2025;388:e077979. DOI: https://doi.org/10.1136/bmj-2023-077979
Systematic Review and Bayesian Meta-Analysis: Higher Protein Delivery May Increase Mortality in Critically Ill Patients
2 Jan, 2025 | 08:30h | UTCBackground: Nutritional guidelines often recommend higher protein doses (approximately 1.2–2.0 g/kg/d) to mitigate muscle loss in critically ill patients. However, recent multicenter trials have raised concerns that elevated protein targets might increase mortality and adversely affect patient-centered outcomes. This study applied a Bayesian approach to synthesize current evidence regarding the effect of higher versus lower protein delivery on mortality, infections, mechanical ventilation duration, and health-related quality of life in critically ill adults.
Objective: To estimate the probability of beneficial or harmful effects of increased protein delivery on clinically important outcomes, with emphasis on quantifying the likelihood of mortality benefit versus risk.
Methods: A systematic review and Bayesian meta-analysis were conducted according to a preregistered protocol (PROSPERO CRD42024546387) and PRISMA 2020 guidelines. Twenty-two randomized controlled trials comparing higher (mean 1.5 g/kg/d) versus lower (mean 0.9 g/kg/d) protein delivery in adult ICU patients were included, ensuring similar energy intake in both groups. A hierarchical random-effects Bayesian model was applied, using vague priors to estimate relative risks for mortality and infections, mean differences for ventilator days, and standardized mean differences for quality of life.
Results: A total of 4,164 patients were analyzed. The posterior probability that higher protein intake increases mortality was 56.4%, compared with a 43.6% probability of any mortality benefit. Probabilities for a clinically relevant (≥5%) mortality decrease were low (22.9%), while the probability of at least a 5% increase reached 32.4%. Infections were slightly more likely with higher protein, although the likelihood of a major detrimental effect remained modest. The probability of a clinically meaningful difference in ventilator days was negligible, suggesting near equivalence for that endpoint. Conversely, quality of life might be negatively impacted by higher protein dosing, although few trials measured this outcome.
Conclusions: Under a Bayesian framework, current evidence suggests that high protein delivery in critically ill patients might pose a meaningful risk of increased mortality. Although a beneficial effect cannot be fully excluded, its probability appears comparatively small. These findings challenge the longstanding assumption that more protein universally translates to better outcomes.
Implications for Practice: Clinicians should exercise caution when aiming for higher protein targets. Individual patient characteristics, such as severity of illness, renal function, and underlying comorbidities, may modulate outcomes. The data support considering a personalized protein prescription rather than routinely pushing intake beyond conventional targets.
Study Strengths and Limitations: Strengths include a robust Bayesian analysis that evaluates probabilities of both benefit and harm across multiple thresholds, as well as the inclusion of recently published large trials. Limitations involve heterogeneity in protein dosing strategies, potential publication bias (indicated by Egger’s test), and limited data on quality of life.
Future Research: Ongoing trials, such as TARGET Protein and REPLENISH, will provide valuable insights into optimal protein dosing, particularly in specific subgroups. Further investigation should explore mechanistic underpinnings of how high protein intake could adversely affect recovery in critically ill patients.
Reference: Heuts S, Lee ZY, Lew CCH, et al. Higher Versus Lower Protein Delivery in Critically Ill Patients: A Systematic Review and Bayesian Meta-Analysis. Critical Care Medicine. December 27, 2024. DOI: http://doi.org/10.1097/CCM.0000000000006562
Review: Frailty in Older Adults
10 Nov, 2024 | 18:03h | UTCIntroduction: Frailty is a state of decreased physiological reserve and increased vulnerability to adverse health outcomes, becoming more prevalent with age. This review by Kim and Rockwood outlines definitions, biological mechanisms, measurement, and management of frailty in older adults, aiming to guide clinical practice.
Key Recommendations:
- Definitions of Frailty: Clinicians should recognize two predominant concepts: the Fried frailty phenotype, defining frailty as a clinical syndrome with features like exhaustion, weakness, slowness, inactivity, and weight loss; and the deficit-accumulation model, quantifying frailty based on accumulated health deficits.
- Biology of Frailty: Understanding biological mechanisms—such as chronic inflammation, cellular senescence, mitochondrial dysfunction, deregulated nutrient sensing, and hormonal changes—is essential for identifying modifiable risk factors and developing targeted interventions.
- Measurement of Frailty: Utilize validated assessment tools appropriate to the clinical context. The Fried frailty phenotype and the deficit-accumulation frailty index are widely used; brief screening tools and performance measures like gait speed can be practical, especially in acute care settings.
- Management and Interventions for Frailty: Management should focus on increasing physiological reserve through multicomponent interventions. Exercise (aerobic and resistance training), combined with nutritional support, comprehensive geriatric assessment, and medication optimization, has been shown to ameliorate frailty and improve mobility, strength, and daily functioning.
- Frailty Screening Before Stressful Treatments: In high-risk clinical contexts such as oncology and surgery, pre-treatment frailty assessment can guide decision-making, personalize care plans, and improve outcomes by reducing treatment-related adverse effects.
- Evidence Gaps and Future Directions: More research is needed on effective strategies for frailty identification, interventions to prevent or reverse frailty, and the cost-effectiveness of frailty-guided care models, particularly in primary care settings.
Conclusion: Incorporating frailty assessment into clinical practice enables personalized, holistic care that aligns with older patients’ health goals and needs. Interventions targeting frailty can enhance physiological reserve, reduce vulnerability to stressors, and improve clinical outcomes. Further research is essential to optimize frailty management strategies and fully realize the benefits of frailty-guided care in our aging society.
RCT: Vitamin K2 Reduces Nocturnal Leg Cramps in Older Adults
28 Oct, 2024 | 18:59h | UTCBackground Nocturnal leg cramps (NLCs) affect 50% to 60% of adults, causing significant discomfort, sleep disturbances, and reduced quality of life. Current treatments lack robust evidence for efficacy and safety, with quinine no longer recommended due to severe adverse effects. Vitamin K2 has shown promise in reducing muscle cramps in dialysis patients, suggesting potential benefits for managing NLCs.
Objective To evaluate whether vitamin K2 supplementation reduces the frequency, duration, and severity of nocturnal leg cramps in older adults compared with placebo.
Methods In this multicenter, double-blind, placebo-controlled randomized clinical trial conducted in China from September 2022 to December 2023, 199 community-dwelling individuals aged 65 years or older with at least two episodes of NLCs over a two-week screening period were enrolled. Participants were randomly assigned in a 1:1 ratio to receive daily oral vitamin K2 (menaquinone-7, 180 μg) or placebo for eight weeks. The primary outcome was the mean number of NLCs per week. Secondary outcomes included cramp duration and severity, measured on a 1 to 10 analog scale.
Results Of the 199 participants (mean age 72.3 ± 5.5 years; 54.3% female), 103 received vitamin K2 and 96 received placebo. Baseline weekly cramp frequency was similar between groups (vitamin K2: 2.60 ± 0.81; placebo: 2.71 ± 0.80). Over eight weeks, the vitamin K2 group experienced a significant reduction in mean weekly cramps to 0.96 ± 1.41, while the placebo group increased to 3.63 ± 2.20 (between-group difference: −2.67; 95% CI, −2.86 to −2.49; P < .001). The vitamin K2 group also showed greater reductions in cramp severity (mean decrease of 2.55 ± 2.12 points vs 1.24 ± 1.16 points in placebo) and duration (mean decrease of 0.90 ± 0.88 minutes vs 0.32 ± 0.78 minutes in placebo). No adverse events related to vitamin K2 were reported.
Conclusions Vitamin K2 supplementation significantly reduced the frequency, severity, and duration of nocturnal leg cramps in older adults, demonstrating both efficacy and safety.
Implications for Practice Vitamin K2 may offer an effective and safe therapeutic option for managing NLCs in older individuals, addressing a significant unmet clinical need in primary care.
Study Strengths and Limitations Strengths include the randomized, double-blind design and focus on an older population; limitations involve the relatively mild symptoms of participants and lack of assessment of quality of life or sleep improvements.
Future Research Further studies should assess the impact of vitamin K2 on sleep quality and quality of life in patients with more severe NLCs and explore the underlying mechanisms of its muscle-relaxing effects.
Phase 2 RCT: Ponsegromab Shows Promise for the Treatment of Cancer Cachexia
23 Sep, 2024 | 21:48h | UTCBackground: Cancer cachexia is a multifactorial syndrome characterized by weight loss, muscle wasting, and reduced quality of life. Elevated levels of growth differentiation factor 15 (GDF-15), a cytokine, have been associated with cachexia. Ponsegromab, a monoclonal antibody that inhibits GDF-15, has shown potential in reversing cachexia in early studies by improving weight, appetite, and physical activity. This phase 2, randomized, double-blind trial aimed to assess the efficacy and safety of ponsegromab in patients with cancer cachexia and elevated GDF-15 levels.
Objective: To evaluate the impact of ponsegromab on body weight, cachexia symptoms, appetite, physical activity, and safety in cancer cachexia patients with elevated GDF-15 levels.
Methods: In this 12-week study, 187 patients with non-small-cell lung cancer, pancreatic cancer, or colorectal cancer and elevated GDF-15 levels (≥1500 pg/mL) were randomized into four groups: ponsegromab 100 mg, 200 mg, 400 mg, or placebo, administered subcutaneously every four weeks. The primary endpoint was the change in body weight from baseline to week 12. Secondary outcomes included appetite and cachexia symptoms, physical activity measured via digital devices, and safety. The trial also included exploratory endpoints like changes in skeletal muscle mass.
Results:
At 12 weeks, patients treated with ponsegromab showed significant weight gain compared to placebo. The median weight gain differences were 1.22 kg in the 100-mg group, 1.92 kg in the 200-mg group, and 2.81 kg in the 400-mg group. Significant improvements in appetite and cachexia symptoms were observed in the 400-mg group compared to placebo. Physical activity, measured by nonsedentary time, also increased by 72 minutes per day in the 400-mg group. Adverse events were reported by 70% of ponsegromab patients and 80% of placebo patients. Serious adverse events occurred at similar rates across groups, but none were deemed related to treatment. No significant safety concerns were identified.
Conclusions: Ponsegromab effectively increased body weight and improved cachexia symptoms in patients with cancer cachexia and elevated GDF-15 levels, supporting GDF-15’s role as a key driver of cachexia. The findings suggest that ponsegromab may be a promising therapeutic option for managing cancer cachexia, with a favorable safety profile.
Implications for Practice: Ponsegromab could represent a targeted therapy for cancer cachexia, addressing weight loss, appetite, and physical function. Clinicians may consider its use for patients with advanced cancers experiencing cachexia, particularly those with elevated GDF-15 levels.
Study Strengths and Limitations: Strengths of the study include its randomized, double-blind design and the use of objective measures such as digital physical activity tracking. Limitations include the relatively short trial duration, and missing physical activity data for some patients. Additionally, the efficacy of ponsegromab across different baseline levels of GDF-15 requires further investigation.
Future Research: Larger and longer-term trials are necessary to confirm the therapeutic benefit of ponsegromab in cancer cachexia. Future research should explore its impact on survival and assess whether GDF-15 inhibition benefits other conditions associated with elevated GDF-15, such as heart failure and chronic kidney disease.
News Release: SCOFF Trial Confirms Fasting Not Necessary Before Cardiac Catheterisation Procedures
7 Sep, 2024 | 10:10h | UTC1 September 2024 – London, United Kingdom – New findings from the SCOFF trial, presented at ESC Congress 2024, suggest that fasting prior to minimally invasive cardiac catheterisation procedures under conscious sedation does not increase the risk of complications. The trial supports reconsidering current guidelines on pre-procedural fasting.
Key Points for Physicians:
– No increased complications: The SCOFF trial found no significant difference in adverse outcomes, such as aspiration pneumonia or hypoglycemia, between patients who fasted and those who ate normally before cardiac catheterisation.
– Improved patient satisfaction: Patients who did not fast reported higher satisfaction, with fewer complaints of discomfort and hunger.
– Potential guideline change: These findings, in line with previous studies like CHOW-NOW and TONIC, challenge the necessity of fasting before such procedures.
The trial’s lead investigator, Dr. David Ferreira (John Hunter Hospital, Australia), emphasized that avoiding fasting may improve patient experience without increasing risks, making it time to reconsider fasting guidelines for these procedures.
Study Overview:
– Trial design: Prospective, randomized, open-label, with blinded endpoint assessment.
– Participants: 716 patients undergoing coronary angiography, coronary intervention, or cardiac implantable electronic device procedures.
– Primary endpoint: Composite of hypotension, aspiration pneumonia, hyperglycemia, and hypoglycemia, showing a lower event rate in the non-fasting group (12.0%) compared to the fasting group (19.1%).
These results are likely to influence future clinical practice, providing greater flexibility for both patients and healthcare systems.
Systematic Review: Nasogastric Feeding Increases Diarrhea and Pain Compared to Nasojejunal Feeding in Acute Pancreatitis – BMC Gastroenterol
18 Aug, 2024 | 19:23h | UTCStudy Design and Population: This systematic review and meta-analysis compared the safety and efficacy of nasogastric (NG) versus nasojejunal (NJ) feeding initiated within 48 hours of hospital admission in patients with moderate to severe acute pancreatitis. The analysis included four randomized controlled trials (RCTs) involving a total of 217 patients.
Main Findings: The review found no significant difference in mortality between NG and NJ feeding groups. However, NG feeding was associated with a higher incidence of diarrhea (RR 2.75, P = 0.02) and pain (RR 2.91, P = 0.002). The risk of infection was also higher in the NG group (6.67% vs. 3.33%, P = 0.027). No significant differences were observed in the need for surgical intervention, the requirement for parenteral nutrition, or the success rates of feeding procedures.
Implications for Practice: The findings suggest that while NG feeding does not increase mortality in acute pancreatitis, it is associated with higher rates of certain complications, particularly diarrhea and pain. Clinicians should consider these risks when choosing a feeding strategy for patients with acute pancreatitis, especially within the critical early 48-hour period post-admission.
RCT: Free Access to Water vs. Fasting Pre-Cesarean Reduces Vomiting and Increases Maternal Satisfaction
25 Mar, 2024 | 11:17h | UTCStudy Design and Population: This randomized controlled trial was carried out at the Obstetric Unit, Universiti Malaya Medical Center from October 2020 to May 2022. A total of 504 women scheduled for planned cesarean delivery under spinal anesthesia were randomized into two groups: 252 were allowed free access to water up until being called to the operating theater, and 252 were required to fast from midnight before the procedure. The study primarily aimed to evaluate the effects of these preoperative oral intake policies on perioperative vomiting and maternal satisfaction.
Main Findings: The results demonstrated significant benefits for the group with free access to water. Specifically, perioperative vomiting was observed in 3.6% of women with water access compared to 9.5% of those fasting, indicating a relative risk reduction. Maternal satisfaction scores were notably higher in the water access group, with median scores of 9 versus 5 for the fasting group. Additional findings included lower reports of thirst, fewer instances of preoperative intravenous hydration, reduced ketone presence in urine, and a lower average number of vasopressor doses needed. Significantly, 95.2% of participants in the water access group would recommend their regimen to a friend, compared to only 39.7% in the fasting group.
Implications for Practice: Allowing free access to water up until the time of surgery for women scheduled for cesarean delivery under spinal anesthesia significantly reduces the risk of perioperative vomiting and improves maternal satisfaction, without adversely affecting post-cesarean recovery or neonatal outcomes. These findings support revising current preoperative fasting guidelines to improve patient experience and potentially enhance clinical outcomes.
ESPEN guideline on nutritional support for polymorbid medical inpatients
7 Aug, 2023 | 14:52h | UTCESPEN guideline on nutritional support for polymorbid medical inpatients – Clinical Nutrition
ESPEN Updated Guideline | Clinical nutrition in the intensive care unit
1 Aug, 2023 | 14:27h | UTC
Personalized nutrition therapy in critical care: 10 expert recommendations
10 Jul, 2023 | 13:36h | UTCPersonalized nutrition therapy in critical care: 10 expert recommendations – Critical Care
How to avoid harm with feeding critically ill patients: a synthesis of viewpoints of a basic scientist, dietitian and intensivist
10 Jul, 2023 | 13:34h | UTC
M-A | Optimizing enteral nutrition delivery by implementing volume-based feeding protocol for critically ill patients
24 May, 2023 | 13:13h | UTC
M-A | Prevalence and outcomes of frailty in unplanned hospital admissions
9 May, 2023 | 14:45h | UTC
Review | What the clinician needs to know about medical nutrition therapy in critically ill patients in 2023
26 Apr, 2023 | 13:59h | UTC
Review | Refeeding Syndrome: diagnostic challenges and the potential of clinical decision support systems
10 Apr, 2023 | 13:28h | UTC
RCT | Low-calorie, low-protein feeding improves recovery time in ventilated adults with shock
22 Mar, 2023 | 13:42h | UTCSummary: The NUTRIREA-3 study aimed to determine the optimal calorie and protein intakes during the acute phase of severe critical illness. The study was a randomized, controlled, multicenter, open-label, parallel-group trial conducted in 61 French intensive care units (ICUs) involving 3044 adults receiving invasive mechanical ventilation and vasopressor support for shock. During the first seven ICU days, participants were randomly assigned to early nutrition with either low or standard calorie and protein targets. The primary endpoints were time to readiness for ICU discharge and day 90 all-cause mortality, while key secondary outcomes included secondary infections, gastrointestinal events, and liver dysfunction.
The study found that early calorie and protein restriction did not decrease mortality. However, it was associated with faster recovery and fewer complications compared to standard calorie and protein targets. The low-calorie, low-protein group had a shorter median time to readiness for ICU discharge and lower proportions of patients with vomiting, diarrhea, bowel ischemia, and liver dysfunction. The proportions of patients with secondary infections did not differ significantly between the two groups.
In conclusion, the NUTRIREA-3 study provides evidence that patients may benefit from restricted calorie and protein intakes during the acute phase of critical illness, as it expedites recovery and reduces the risk of complications.
Article: Low versus standard calorie and protein feeding in ventilated adults with shock: a randomised, controlled, multicentre, open-label, parallel-group trial (NUTRIREA-3) – The Lancet Respiratory Medicine (free registration required)
Commentary on Twitter
NEW Research—Early calorie & protein restriction did not decrease mortality but was associated w/ faster recovery & fewer complications than standard intake targets
NUTRIREA-3 from Prof Jean Reignier & co https://t.co/VCS72qxLPD
Being presented @ISICEM today! #ISICEM23 pic.twitter.com/TpoJnwHP8P
— The Lancet Respiratory Medicine (@LancetRespirMed) March 21, 2023
Review | Nutritional management of the infant with chronic kidney disease stages 2–5 and on dialysis
9 Mar, 2023 | 14:18h | UTC
RCT | Caffeine did not reduce time to first bowel movement after laparoscopic colectomy
1 Mar, 2023 | 13:41h | UTCCaffeine for intestinal transit after laparoscopic colectomy: randomized clinical trial (CaCo trial) – British Journal of Surgery (link to abstract – $ for full-text)
Commentary on Twitter
In BJS' December issue: Caffeine for intestinal transit after laparoscopic colectomy: randomized clinical trial (CaCo trial) https://t.co/6z1cboAxi0 @bplwijn @des_winter @ksoreide @MalinASund @evanscolorectal @nfmkok @paulo_sutt @robhinchliffe1 @young_bjs pic.twitter.com/yGtXiIwgq0
— BJS (@BJSurgery) December 28, 2022
Review | (Mal)nutrition in critical illness and beyond
28 Feb, 2023 | 13:28h | UTC(Mal)nutrition in critical illness and beyond: a narrative review – Anaesthesia
ESPEN practical guideline | Home parenteral nutrition
20 Feb, 2023 | 12:21h | UTCSummary: Home parenteral nutrition (HPN) is a form of nutrition support where a patient receives intravenous nutrition at home. It is used for patients who cannot receive adequate nutrition through oral or enteral routes, such as those with intestinal failure, severe inflammatory bowel disease, or other gastrointestinal disorders. HPN can be a life-saving therapy, but it requires careful patient selection, as well as ongoing monitoring and management by a multidisciplinary team. The ESPEN guideline aims to provide practical guidance on the use of HPN, including the nutritional and metabolic aspects of care and the practical considerations of administering HPN at home. The guideline also emphasizes the importance of patient-centered care and shared decision-making, highlighting the need for regular assessment and monitoring of patients.
Article: ESPEN practical guideline: Home parenteral nutrition – Clinical Nutrition
M-A | The rate and assessment of muscle wasting during critical illness
17 Feb, 2023 | 12:55h | UTC
Commentary on Twitter
A Review published in @Crit_Care analyzes the data of ICU muscle wasting studies and reports that critically ill patients lose nearly 2% of skeletal muscle per day during the first week of ICU admission.https://t.co/qW5jzbWRSk
— BMC (@BioMedCentral) January 8, 2023
Review | Preoperative frailty screening, assessment and management
16 Feb, 2023 | 14:37h | UTCPreoperative frailty screening, assessment and management – Current Opinion in Anaesthesiology
Position Paper | Enteral nutrition in preterm infants
30 Jan, 2023 | 00:54h | UTC